Robert E. Landry - Dec 1, 2022 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
EVP Finance CFO
Signature
/s/**Robert E. Landry
Stock symbol
REGN
Transactions as of
Dec 1, 2022
Transactions value $
-$943,825
Form type
4
Date filed
12/2/2022, 03:05 PM
Previous filing
Nov 2, 2022
Next filing
Dec 12, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Options Exercise $955K +2.5K +8.7% $381.92 31.2K Dec 1, 2022 Direct F1
transaction REGN Common Stock Tax liability -$1.44M -1.89K -6.05% $760.35 29.4K Dec 1, 2022 Direct F1
transaction REGN Common Stock Sale -$440K -582 -1.98% $756.50 28.8K Dec 2, 2022 Direct F1
transaction REGN Common Stock Sale -$12.2K -16 -0.06% $759.90 28.8K Dec 2, 2022 Direct F1
transaction REGN Common Stock Sale -$9.12K -12 -0.04% $760.19 28.7K Dec 2, 2022 Direct F1
holding REGN Common Stock 250 Dec 1, 2022 By 401(k) Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -2.5K -26.88% $0.00 6.8K Dec 1, 2022 Common Stock 2.5K $381.92 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
F2 The stock option award vests in four equal annual installments, commencing one year after the date of grant.